|Day Low/High||41.70 / 45.55|
|52 Wk Low/High||24.02 / 68.05|
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Appointment Strengthens Management Team as Company Advances Clinical Development of Voxelotor, a Potential Disease-Modifying Therapy for Sickle Cell Disease
It is important to note that watching for a reversal is much different than being short.
The bears are likely to be increasingly bold if there's a failed bounce.
It would be a longer-term positive if the overbought conditions are alleviated.
You have to wonder how much longer we can run without a pullback of at least 2%.
There is still a very strong appetite for individual stocks with momentum.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Global Blood Therapeutics Inc , where a total volume of 6,399 contracts has been traded thus far today, a contract volume which is representative of approximately 639,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.1% of GBT's average daily trading volume over the past month, of 1.5 million shares.
Voxelotor is First Investigational Treatment for SCD to Receive Breakthrough Therapy Designation
Investors in Global Blood Therapeutics Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GBT options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.
Data to be Highlighted in ASH Press Briefing and Company to Host Investor Webcast on Monday, December 11, at 8:15 p.m. ET/5:15 p.m. PT to Discuss Data
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.